



## Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

June 8, 2023

### Company to showcase pipeline developments across lead programs in recurrent glioblastoma and leptomeningeal metastases in two poster presentations at SNMMI Annual Meeting

AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- [Plus Therapeutics, Inc.](#) (Nasdaq: [PSTV](#)) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it will exhibit at both the Society for NeuroOncology's (SNO) Pediatric Conference, taking place June 22-24, 2023 in Washington, D.C., and the Society of Nuclear Medicine & Molecular Imaging's (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago, Illinois.

In addition, at the SNMMI Annual Meeting, Norman LaFrance, M.D., Chief Medical Officer, will present data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium ( $^{186}\text{Re}$ ) obisbameda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM), respectively.

#### Details of SNMMI poster presentations:

**Title** Safety and Feasibility Results from a Phase 1/2 Clinical Trial of  $^{186}\text{Re}$  (Rhenium-186 Nanoliposome) ( $^{186}\text{Re}$ ) Obisbameda in Recurrent Glioma: The ReSPECT-GBM Trial [P988]

**Date** June 26, 2023, 10:05-10:15 a.m. CT / 11:05 a.m. ET

**Session** SS25 Head/Neck and Melanoma

**Title** Preliminary Clinical Data in The Phase 1/2a Dose Escalation Trial of  $^{186}\text{Re}$  (Rhenium-186 Nanoliposome) ( $^{186}\text{Re}$ ) Obisbameda in Leptomeningeal Metastases (LM): The ReSPECT-LM Trial [P978]

**Date** June 27, 2023, 1:00-1:30 p.m. CT / 2:00-2:30 p.m. ET

**Session** MTA06-B13 Meet the Author: Neurosciences/Oncology, Basic & Translational - Group B

A copy of the presentations will be made available under the Presentations tab of the Investors section of the Company's website following the meeting at <https://ir.plustherapeutics.com>.

#### **About Plus Therapeutics**

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit <https://plustherapeutics.com/>.

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "designed to," "will," "can," "potential," "focus," "preparing," "next steps," "possibly," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of  $^{186}\text{Re}$  including the ability of  $^{186}\text{Re}$  to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company's future performance including the next steps in developing the Company's current assets; the Company's clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of  $^{186}\text{Re}$ ; the continued evaluation of  $^{186}\text{Re}$  including through evaluations in additional patient cohorts; and the intended functions of the Company's platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company's actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company's product candidates and therapies, the results of the Company's research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company's liquidity and capital resources and its ability to raise additional cash, the outcome of the Company's partnering/licensing efforts, risks associated with laws or regulatory requirements

applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading "Risk Factors" in the Company's Securities and Exchange Commission filings, including in the Company's annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

**Investor Contact**

Peter Vozzo  
ICR Westwicke  
(443) 377-4767  
[Peter.Vozzo@westwicke.com](mailto:Peter.Vozzo@westwicke.com)

**Media Contact**

Terri Clevenger  
ICR Westwicke  
(203) 856-4326  
[Terri.Clevenger@westwicke.com](mailto:Terri.Clevenger@westwicke.com)